Last updated: March 11, 2026
What is the Product?
NDC 50742-0612 corresponds to Xeljanz (tofacitinib) oral tablets, a Janus kinase (JAK) inhibitor indicated for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other immune-mediated conditions. It is marketed by Pfizer.
Market Overview
Market Size and Growth
The global JAK inhibitor market was valued at approximately $8.4 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 12% from 2022 to 2028, driven by increasing adoption in autoimmune disorders and unmet needs in severe cases.
Key Competitors
Major competitors include:
- AbbVie’s Rinvoq (upadacitinib): Approved for rheumatoid arthritis, with a market share of 25% in the JAK inhibitor segment.
- Gilead’s Jyseleca (filgotinib): Limited US market access, but significant sales in Europe.
- AbbVie's Olumiant (baricitinib): Approved for rheumatoid arthritis, capturing 15% market share.
- Other generics and biosimilars entering the market as patents expire.
Market Penetration
Xeljanz has been on the market since 2012. It maintains a lead in rheumatoid arthritis indications, with annual US sales around $1.3 billion in 2022. Its market share is offset by newer entrants with improved safety profiles.
Regulatory and Patent Landscape
- Patent expiry: Patent protection for Xeljanz is expected to expire in the US by 2029, opening opportunities for biosimilar competition.
- Regulatory status: Approved by FDA in 2012 for rheumatoid arthritis; expanded indications in ulcerative colitis (2018) and psoriatic arthritis.
Pricing Strategies
Current Pricing
- US retail price: Approximately $6,500–$6,800 per 30-day supply (30 tablets of 5 mg).
- Cost per patient annually: Estimated at $78,000 based on average dosing and prices.
Pricing Comparisons
| Drug |
Typical Monthly Cost |
Patent Status |
Indications |
| Xeljanz (tofacitinib) |
~$6,500 |
Expired patents in some markets |
RA, UC, PsA |
| Rinvoq (upadacitinib) |
~$7,200 |
Patented until ~2030 |
RA, UC |
| Olumiant (baricitinib) |
~$5,800 |
Patented until ~2030 |
RA |
Price Trends and Projections
- US prices for Xeljanz have remained relatively stable from 2018-2022.
- Price erosion expected after patent expiry (~2029) for biosimilar entry.
- In Europe, price negotiations involve risk-sharing agreements, leading to discounts around 20% on list prices.
Market Dynamics and Future Factors
- Biosimilar Entry: Biosimilars could reduce prices by 30-50% upon patent expiry.
- New Indications: Expansion into additional autoimmune conditions could sustain revenue.
- Safety concerns: Black box warnings on serious infections and thrombosis have limited uptake in some markets, impacting sales potential.
Price Projections (2023–2030)
| Year |
Estimated Average Price |
Key Assumptions |
Notes |
| 2023 |
~$6,500–$6,800 |
Current market, no significant price changes |
Competitive pressures from biosimilars unlikely |
| 2025 |
~$6,200–$6,400 |
Slight market saturation, formulary access |
Cost containment measures in healthcare systems |
| 2027 |
~$5,800–$6,000 |
Increasing biosimilar presence, patent still intact |
Continued price stability or minor discounts |
| 2029 |
~$3,500–$4,000 |
Patent expiry, biosimilar competition begins |
Potential for off-brand or biosimilar options |
| 2030+ |
<$3,000 |
Biosimilars become dominant |
Likely to see increased competition and discounts |
Key Takeaways
- Xeljanz remains a significant revenue generator for Pfizer, especially in rheumatoid arthritis.
- Market growth continues to be driven by expanding indications and unmet needs.
- Price stability persists until patent expiry in 2029; biosimilar entry could halve prices thereafter.
- Competition from newer JAK inhibitors like Rinvoq influences pricing and market share.
- Future pricing depends heavily on biosimilar market developments and regulatory pathways.
FAQs
1. What factors could accelerate or delay biosimilar entry?
Patent litigation, regulatory approvals, and market dynamics influence biosimilar entry timing. Patent litigation delays could push biosimilars to market past 2029.
2. How do pricing trends vary internationally?
In Europe, pricing is negotiated through rebates and risk-sharing agreements, often resulting in discounts up to 20%. Emerging markets typically see lower prices due to healthcare budget constraints.
3. Are there recent regulatory updates impacting Xeljanz?
FDA approved a supplemental label expansion for ulcerative colitis in 2018. In 2022, some safety warnings were reinforced due to adverse event reports, affecting prescribing behavior.
4. What is the impact of safety concerns on market share?
Safety warnings for blood clots and infections have led some physicians to prefer alternative therapies, especially in patients with cardiovascular risk factors.
5. How does patent expiration impact company's revenue projections?
Patent expiration in 2029 will likely reduce sales by up to 50% due to biosimilar competition, sharply decreasing revenue from Xeljanz unless new indications or formulations are commercialized.
References
- GlobalData. (2022). JAK inhibitors market report.
- IQVIA Institute. (2022). The US pharmaceutical market.
- FDA. (2022). Safety label updates for JAK inhibitors.
- Pfizer. (2022). Xeljanz product information.
- Scrip Intelligence. (2023). Biotech patent landscape.
